At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Baricitinib (LY3009104) 2 mg +1 moredrug
Likely dose
Baricitinib (LY3009104) 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus
In Brief
A Phase 2 clinical trial evaluating Baricitinib (LY3009104) 2 mg and Baricitinib (LY3009104) 4 mg for Cutaneous Lichen Planus. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This research study is evaluating the safety and efficacy of Baricitinib in treating Cutaneous Lichen Planus (LP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous Lichen Planus
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartJan 2022
First PostedJan 2022
Primary CompletionMay 2023
TodayJul 2026
First PostedJan 12, 2022
Enrollment StartJan 11, 2022
Primary CompletionMay 17, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.5 years ago
Interventions
Baricitinib (LY3009104) 2 mgdrug
2 mg orally administered once daily for 16 weeks
Baricitinib (LY3009104) 4 mgdrug
4 mg orally administered once daily for 12 weeks